Pediatric inflammatory bowel diseases and the risk of lymphoma: Should we revise our treatment strategies?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 48, Issue 3, 2009, Pages 257-267

  Cucchiara, Salvatore ^a   Escher, Johanna C ^b   Hildebrand, Hans ^c   Amil Dias, Jorge ^d   Stronati, Laura ^a   Ruemmele, Frank M ^e,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anti TNF; Biologicals; Crohn; Inflammatory bowel disease; Lymphoma; Pediatric

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN G1; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; CANCER RISK; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DRUG SAFETY; ENTERIC FEEDING; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEPSIS; T CELL LYMPHOMA; TUBERCULOSIS; ULCERATIVE COLITIS; CHILD; DRUG ANTAGONISM; DRUG COMBINATION;

BIOLOGICAL PRODUCTS; CHILD; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, T-CELL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650400522     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31818cf555     Document Type: Review

References (82)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641-57.
2. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72.
3. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57.
4. Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomo-dulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006;8:499-505.
5. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299-307.
6. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006; 8:506-12.
7. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007; 67:1703-23.
8. Biancone L, Calabrese E, Petruzziello C, et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:78-91.
9. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
10. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
11. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120 (Suppl 12):1-39.
12. McNally RJ, Parker L. Environmental factors and childhood acute leukemias and lymphomas. Leuk Lymphoma 2006;47:583-98.
13. Harris NL, Stein H, Coupland SE, et al. New approaches to lymphoma diagnosis. Hematology Am Soc Hematol Educ Program 2001:194-220.
14. Hagenbeek A, Bischof Delaloye A. Editorial perspective - advances in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44 (Suppl 4):S1-4.
15. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:161-8.
16. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
17. Bargen JA. Chronic ulcerative colitis associated with malignant disease. Arch Surg 1928;17:561-76.
18. Hughes RK. Reticulum cell sarcoma: a case possibly originating in regional enteritis. Ann Surg 1955;21:770-3.
19. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol/Hematol 2005;56:169-78.
20. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
21. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
22. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22.
23. Persson PG, Karlén P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107:1675-9.
24. Karlén P, Löfberg R, Broström O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94:1047-52.
25. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119:647-53.
26. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-21.
27. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-9.
28. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
29. Persson PG, Karlén P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107:1675-9.
30. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppres-sive treatment. Aliment Pharmacol Ther 2001;15:1101-8.
31. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007; 56:293-303.
32. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007; 16:164-71.
33. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
34. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47:514-9.
35. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease - a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
36. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;102:2804-12.
37. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:427-30.
38. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
39. Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis 2007;13:769-96.
40. Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003; 98:608-12.
41. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126:19-31.
42. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
43. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33.
44. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3-12.
45. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab and other Crohn's disease therapies - Treat™ Registry data with nearly 20,000 patient-years and follow-up. Gastroenterology 2007;132:A178.
46. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017-24.
47. Symmons DP. Lymphoma rheumatoid arthritis - again. Rheumatology (Oxford) 2007;46:1-2.
48. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
49. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-85.
50. Kadin M, Kamoun M, Lamberg J. Erythrophagocytic Tγ lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med 1981;304:648-53.
51. Belhadj K, Reyes F, Farcewt J-P, et al. Hepatosplenic γδT-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9.
52. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2006:317-22.
53. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/ beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas: identification of a subset of γδT-cell lymphomas. Am J Pathol 1990;137:617-28.
54. Percy C, Smith M, Linet M, et al. Lymphomas and reticuloen-dothelial neoplasms. In: Ries LA, Smith MA, Gurney JG, et al (editors). Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program. NIH Pub. No. 99- 4649; 1999:35-50.
55. Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004;4:1534-8.
56. Wu H, Wasik MA, Przbylski G, et al. Hepato-splenic gamma-delta T-cell lymphoma as a late onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol 2000; 113:487-96.
57. Lemann M, de La Valussiere G, Bouhnik Y, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): long-term follow-up of patients [abstract]. Gastroenterology 1998; 114:A1020.
58. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gamma delta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3.
59. Mittal S, Milner BJ, Johnston PW, et al. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006;76:531-4.
60. Keller KM, Magdefrau C, Bohl L, et al. Hepatosplenic T-cell-lymphoma in a 15-year-old boy with ulcerative colitis treated with azathioprine for 9 years. J Pediatr Gastroenterol Nutr 2007; 44:e259.
61. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71.
62. Markowitz J, Hyams J, Mack D, et al., Pediatric IBD Collaborative Research GroupCorticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124-9.
63. Hyams J, Markowitz J, Lerer T, et al., Inflammatory Bowel Disease Collaborative Research GroupThe natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4:1118-23.
64. Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis 2007;13:1430-8.
65. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006;23:451-63.
66. Hyams J, Crandall W, Kugathasan S, et al., REACH Study Group-Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
67. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39.
68. Loftus EV Jr. Biologic therapy in Crohn's disease: review of the evidence. Rev Gastroenterol Disord 2007;7 (Suppl 1):S3-12.
69. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007; 67:1703-23.
70. Hanauer SB. Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease. Curr Gastroenterol Rep 2007;9:487-8.
71. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
72. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641-57.
73. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8.
74. Lichtenstein GR, Diamond RH, Wagner C, et al. Infliximab adminis-teredas3-doseinduction followedbyscheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators [abstract]. Gastroenterology 2007;132:A146.
75. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
76. Hanauer SB, Feagan BG, Lichtenstein GR, et al., ACCENT I Study GroupMaintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
77. Bamias G, Nyce MR, De La Rue SA, et al., American College of Physicians; American Physiological SocietyNew concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005;143:895-904.
78. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65.
79. Sandborn WJ, Feagan BG, Stoinov S, et al., PRECISE 1 Study InvestigatorsCertolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
80. Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn's disease: Fact or fantasy? J Pediatr 2000;136:285-91.
81. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
82. Day AS, Whitten KE, Sidler M, et al. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008;27:293-307.